Recommended

Sarepta’s DMD drug Elevidys issued FDA label update
Rare disease gene therapy granted European first approval
Johnson & Johnson agrees $3bn oncology acquisition
European Commission grants EU first for J&J’s Simponi biosimilar
Researchers validate approach that supports animal-based pyrogen test replacement
ON DEMAND webinar: automating QC testing for radiopharmaceutical production
Insmed secures EU approval for Brinsupri (brensocatib)
Moderna invests over $140m to onshore mRNA medicine manufacturing in US
news

Bioavailability tests could improve personalised medicine approaches, study shows

7
SHARES

Researchers have demonstrated that bioavailability tests in patients to reveal anti-drug antibody levels could aid personalised medicine.

A study has revealed that patients who are treated with tumour necrosis factor alpha inhibitors (TNFi) but do not respond to therapy could adjust their doses or switch to different drugs following bioavailability tests. The researchers say this would enable a personalised medicine approach for patients.  

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The international study was led by researchers from multiple institutions in Italy. The team conducted a multicentre, cross-sectional study on different methods for bioavailability testing. They conducted their study in 70 patients with rheumatoid arthritis (RA) or juvenile idiopathic arthritis (JIA). The patients were treated with either adalimumab or etanercept and were subsequently tested for drug and anti-drug antibody (ADAb) levels, which indicate the level of drug bioavailability. 

To study bioavailability, the researchers used an enzyme-linked immunosorbent assay (ELISA) and a cell-based functional assay (reporter gene assay – RGA) for ADAb detection in patient samples. They highlight that two assays were used to better define the pharmacology of TNFi. 

In the patients, the researchers tested for drug and ADAb levels on the first day of treatment, then after three and six months of treatment with adalimumab or etanercept. According to the team, none of the patients used TNFi before the study and TNFi was used only in combination with methotrexate. 

The researchers found ADAb responses in adalimumab- or etanercept-treated groups that were associated with a decrease in pharmacological drug availability in the blood. Comparable results were found for the adalimumab-treated group in the prospective study which also showed a relationship between drug and ADAb levels and the loss of clinical response.

The scientists conclude that altogether, their findings support drug and ADAb monitoring in the real-world clinical setting to enable individualised treatment and reduce disability in chronic inflammatory arthritis, overall increasing bioavailability of the drugs being used. 

The study results can be found in Autoimmunity Reviews. 

Share via
Share via